Tier 4 — mechanistic

Health Benefits of Quercetin in Age-Related Diseases

Deepika, Pawan Kumar Maurya
Molecules (Basel, Switzerland) 2022 27(8):2498

Bibliography

PubMed
PMID 35458696
PubMed Central
PMC9032170
DOI
10.3390/molecules27082498
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare no conflict of interest.

Study snapshot

DesignNarrative review of age-related disease mechanisms
ModelNarrative or mixed evidence review
SamplePredominantly mechanistic and preclinical literature; no new trial cohort
InterventionQuercetin across neurological, metabolic, cancer, and inflammatory models
DurationSelected literature from the preceding decade
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2022, this source examined senescence and longevity. Its evidence base was Predominantly mechanistic and preclinical literature; no new trial cohort. It evaluated Quercetin across neurological, metabolic, cancer, and inflammatory models across Selected literature from the preceding decade.

The review proposes several pathways through which quercetin might influence age-related disease.

Broad preventive claims exceed direct human outcome evidence. It does not demonstrate human lifespan extension, dementia prevention, or reliable brain exposure after oral dosing.

Continue with Quercetin Data Center

For topic-level interpretation, read Is Quercetin a Senolytic? Human Evidence vs Longevity Claims. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The review proposes several pathways through which quercetin might influence age-related disease.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.

What this study can and cannot tell us

  • Broad preventive claims exceed direct human outcome evidence. It does not demonstrate human lifespan extension, dementia prevention, or reliable brain exposure after oral dosing.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology